Abstract:BRDT, BRD2, BRD3, and BRD4 comprise the bromodomain and extraterminal (BET) subfamily which contain two similar tandem bromodomains (BD1 and BD2). Selective BD1 inhibition phenocopies effects of tandem BET BD inhibition both in cancer models and, as we and others have reported of BRDT, in the testes. To find novel BET BD1 binders, we screened >4.5 billion molecules from our DNA-encoded chemical libraries with BRDT-BD1 or BRDT-BD2 proteins in parallel. A compound series enriched only by BRDT-BD1 was resynthesized off-DNA, uncovering a potent chiral compound, CDD-724, with >2,000-fold selectivity for inhibiting BRDT-BD1 over BRDT-BD2. CDD-724 stereoisomers exhibited remarkable differences in inhibiting BRDT-BD1, with the R-enantiomer (CDD-787) being 50-fold more potent than the S-enantiomer (CDD-786). From structure–activity relationship studies, we produced CDD-956, which maintained picomolar BET BD1 binding potency and high selectivity over BET BD2 proteins and had improved stability in human liver microsomes over CDD-787. BROMOscan profiling confirmed the excellent pan-BET BD1 affinity and selectivity of CDD-787 and CDD-956 on BD1 versus BD2 and all other BD-containing proteins. A cocrystal structure of BRDT-BD1 bound with CDD-956 was determined at 1.82 Å and revealed BRDT-BD1–specific contacts with the αZ and αC helices that explain the high affinity and selectivity for BET BD1 versus BD2. CDD-787 and CDD-956 maintain cellular BD1-selectivity in NanoBRET assays and show potent antileukemic activity in acute myeloid leukemia cell lines. These BET BD1-specific and highly potent compounds are structurally unique and provide insight into the importance of chirality to achieve BET specificity.

Discovery of Novel CBP Bromodomain Inhibitors Through TR-FRET-based High-Throughput Screening

Discovery of a Potent and Selective CBP Bromodomain Inhibitor (Y08262) for Treating Acute Myeloid Leukemia

Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity

CBP/p300 bromodomain: new promising epigenetic target

Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain

Discovery of Selective BPTF Bromodomain Inhibitors by Screening and Structure-Based Optimization.

Discovery of Pyrrolo[3,2-d]pyrimidin-4-one Derivatives As a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain

Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.

Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia

Discovery of a highly potent CECR2 bromodomain inhibitor with 7H-pyrrolo[2,3-d] pyrimidine scaffold

Discovery and Optimization of 1-(1 H -Indol-1-yl)ethanone Derivatives As CBP/EP300 Bromodomain Inhibitors for the Treatment of Castration-Resistant Prostate Cancer

Discovery of High-Affinity Inhibitors of the BPTF Bromodomain

Discovery of Highly Potent, Selective, and Orally Efficacious P300/cbp Histone Acetyltransferases Inhibitors

Classical Molecular Dynamics and Metadynamics Simulations Decipher the Mechanism of CBP30 Selectively Inhibiting CBP/p300 Bromodomains

Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression

Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer

Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.

Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors

Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections

Discovery of Novel Benzimidazole Derivatives As Potent P300 Bromodomain Inhibitors with Anti-Proliferative Activity in Multiple Cancer Cells.

Discovery of Novel Small Molecule Induced Selective Degradation of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD4 and BRD2 with Cellular Potencies.